Please check your internet connection and try again.
## Tus%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd (Tussobimycin)
### Overview
Tus%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd is a macrolide antibiotic. It is used to treat bacterial infections.
### Primary Indications
* **Respiratory Tract Infections:** Such as pneumonia, bronchitis, and pharyngitis/tonsillitis caused by susceptible organisms.
* **Skin and Soft Tissue Infections:** Uncomplicated infections caused by susceptible organisms.
* **Other Infections:** Including otitis media and certain sexually transmitted infections.
### Adult Dosing
* **Common Dosing:** 500 mg orally once daily.
* **Maximum Daily Dose:** Typically 500 mg orally once daily. Specific indications may allow for higher doses, but this is uncommon.
### Pediatric Dosing
* **Dosing is based on weight:** Typically 10 mg/kg orally once daily, not to exceed 500 mg per dose.
* **Age Restrictions:** Generally approved for children over 6 months of age. Specific formulations may be available for younger infants.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary based on severity of impairment and clinical response.
* **Renal Impairment:** No dose adjustment is typically required for mild to moderate renal impairment. For severe renal impairment (CrCl < 30 mL/min), dose reduction by 50% may be considered.
### Contraindications
* Hypersensitivity to Tus%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd or other macrolide antibiotics.
* Concomitant use with certain medications that prolong the QT interval or are substrates of CYP3A4 (e.g., pimozide, quinidine, cisapride, ergotamine derivatives).
### Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain.
* **Less Common:** Headache, dizziness, rash, pruritus, elevated liver enzymes.
* **Serious:** QT prolongation, *Clostridioides difficile*-associated diarrhea, severe allergic reactions (anaphylaxis), hepatotoxicity.
### Key Drug Interactions
* **CYP3A4 Substrates:** Tus%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd inhibits CYP3A4, potentially increasing serum concentrations of drugs metabolized by this enzyme (e.g., warfarin, theophylline, carbamazepine, cyclosporine, statins).
* **QT Prolonging Agents:** Increased risk of QT prolongation and arrhythmias.
* **Antacids:** May decrease absorption. Administer at least 2 hours before or after antacids.
### Monitoring
* **Clinical Efficacy:** Monitor for improvement of signs and symptoms of infection.
* **Adverse Effects:** Monitor for gastrointestinal distress, signs of hypersensitivity, and *C. difficile* infection.
* **Liver Function:** Consider baseline and periodic monitoring of liver enzymes, especially in patients with pre-existing hepatic dysfunction or those on prolonged therapy.
* **ECG:** Consider baseline ECG and monitoring for QT interval prolongation in patients with risk factors.
### Clinical Pearls
* The once-daily dosing of Tus%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd may improve adherence compared to multiple daily doses.
* It can be taken with or without food.
* Ensure adequate hydration during treatment.
* For sexually transmitted infections, partner notification and treatment may be necessary.
***
*Disclaimer: This information is intended for clinical use and does not replace detailed prescribing information. Always consult the official product monograph or other authoritative sources for complete and up-to-date information before prescribing or dispensing.*
